ArticleIn vivo (Athens, Greece)
Alternate-day S-1 Oral Therapy for Frail Patients With Metastatic Colorectal and Pancreatic Cancer.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Alternate-day Capecitabine Plus Trastuzumab for Frail HER2-positive Gastric Cancer: A Pilot Case Series.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimStandard therapies are difficult to implement in vulnerable patients. S-1 alternative daily therapy has been reported to be a low-burden drug therapy for metastatic colorectal cancer in elderly patients. The vulnerable elders survey-13 (VES-13) is a tool to identify vulnerable elderly patients. In this study, we investigated the utility of simultaneous and serial measurements of the VES-13 and cancer prognostic factors, neutrophil-to-lymphocyte ratio (NLR) and tumor markers (TM), during chemotherapy in patients receiving S-1 every other day. PATIENTS AND
methodsWe studied five patients with metastatic colorectal cancer and eight patients with pancreatic cancer who received S-1 on alternate days. The NLR, TM levels, and VES-13 scores were measured monthly before and during chemotherapy. A scatterplot of NLR on the horizontal axis and TM levels on the vertical axis was plotted together with the VES-13.
resultsThe NLR and VES-13 scores showed a positive correlation, and both increased in cases of bowel obstruction or enteritis. Following the evaluation of progressive disease, two patients with colon cancer and two with pancreatic cancer were eligible to switch to the standard treatment regimen.
conclusionAlternate-day S-1 therapy appears to be a feasible and effective treatment option for frail patients with metastatic colorectal and pancreatic cancer. Continuous monitoring of the NLR and VES-13 scores can aid in the stratification of patients, ensuring that treatment intensity is appropriately matched to the patient's condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.